Noninferiority and equivalence trials: Deciphering 'similarity' of medical interventions

Statistics in Medicine

Volumn 27, Issue 3, 2008, Pages 343-352

  Powers, John H ^a,b,c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; PENICILLIN G;

ACUTE OTITIS MEDIA; CHRONIC BRONCHITIS; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFECT; DRUG TREATMENT FAILURE; EFFECT SIZE; HUMAN; METHODOLOGY; NONHUMAN; NOTE; PNEUMONIA; RANDOMIZATION; RESEARCH ETHICS; RISK BENEFIT ANALYSIS; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; SYSTEMATIC ERROR;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; RESEARCH DESIGN; SAMPLE SIZE; THERAPEUTIC EQUIVALENCY; UNITED STATES;

EID: 38949129367     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3138     Document Type: Note

References (26)

1. Blackwelder WC. Proving the null hypothesis in clinical trials. Controlled Clinical Trials 1982; 3(4):345-353.
2. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Annals of Internal Medicine 2000; 133(6):455-463.
3. Fleming TR. Current issues in noninferiority trials. Statistics in Medicine 2007; in press.
4. International Conference on Harmonisation. Statistical Principles for Clinical Trials (ICH E-9), 2000. Available at: http://www.ich.org/ MediaServer.jser?ID=485&MODE=GLB.
5. International Conference on Harmonisation. Choice of Control Group and Related Issues in Clinical Trials (ICH E-10), 2000. Available at: http://www.ich.org/MediaServer.jser?ID=486&MODE=GLB.
6. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. The New England Journal of Medicine 2006; 355(20):2071-2084.
7. Definition of similar. Encarta Online Dictionary, 2007. Available at: http://encarta.msn.com/dictionary_/similar.html.
8. Definition of equivalent. Encarta Online Dictionary, 2007. Available at: http://encarta.msn.com/dictionary_1861608985/ equivalent.html.
9. Greene WL, Concato J, Feinstein AR. Claims of equivalence in medical research: are they supported by the evidence? Annals of Internal Medicine 2000; 132(9):715-722.
10. LeHenanff A, Giraudeau B, Baron G, Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. Journal of the American Medical Association 2006; 295(10):1147-1151.
11. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. Journal of the American Medical Association 2006; 295(10):1152-1160.
12. Goodman SN. Toward evidence-based medical statistics. 1: the P value fallacy. Annals of Internal Medicine 1999; 130(12):995-1004.
13. Powers JH. Increasing the efficiency of clinical trials of antimicrobials: the scientific basis of substantial evidence of effectiveness of drugs. Clinical Infectious Diseases 2007; 45(Suppl 2):S153-S162.
14. U.S. Government Printing Office. U.S. Code of Federal Regulations, Title 21, Part 314.126, 2007. Available at: http://a257.g.akamaitech.net/ 7/257/2422/10apr20061500/edocket.access.gpo.gov/cfr_2006/aprqtr/ 21cfr314.126.htm.
15. U.S. Food and Drug Administration. Transcript of the FDA/IDSA/PhRMA Workshop on Antimicrobial Drug Development, 2004. Available at: http://www.fda.gov/cder/present/idsaphrma/default.htm.
16. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine 1987; 106(2):196-204.
17. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. Journal of the American Medical Association 1995; 273(12):957-960.
18. Powers JH. Diagnosis and treatment of acute otitis media: evaluating the evidence. Infectious Disease Clinics of North America 2007; 21(2)409-426, vi.
19. Bailar III JC. The promise and problems of meta-analysis. The New England Journal of Medicine 1997; 337(8):559-561.
20. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. The New England Journal of Medicine 1997; 337(8):536-542.
21. Finland M. Empiric therapy for bacterial infections: the historical perspective. Reviews of Infectious Diseases 1983; 5(Suppl 1):S2-S8.
22. U.S. Food and Drug Administration. Guidance for Industry Antibacterial Drug Products Use of Non-Inferiority Studies to Support Approval, 2007. Available at: www.fda.gov/cder/guidance/7884dft.htm.
23. Snapinn SM. Noninferiority trials. Current Control Trials in Cardiovascular Medicine 2000; 1(1):19-21.
24. European Medicines Agency. Committee for Proprietary Medicinal Products. Choice of Non-Inferiority Margin, 2005. Available at: www.emea.europa.eu/pdfs/human/ewp/215899er.pdf.
25. U.S. Food and Drug Administration. Transcript of Anti-infective Drugs Advisory Committee. Non-Inferiority Trials in Anti-infectives, 2002. Available at: www.fda.gov/ohrms/dockets/ac/02/transcripts/ 3837tl.pdf.
26. Pocock SJ. The pros and cons of noninferiority trials. Fundamental and Clinical Pharmacology 2003; 17(4): 483-490.